60 Degrees Pharmaceuticals (SXTP) Gross Margin (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Gross Margin of 47.12% for Q1 2026, down 808.0% year-over-year from 6.66% in Q1 2025, and down 21.76% quarter-over-quarter from 60.22% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Gross Margin (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Gross Margin for 5 consecutive years, with 47.12% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 808.0% year-over-year to 47.12%; the TTM figure through Mar 2026 stood at 20.9% (down 2010.0% YoY), while the FY2025 annual figure was 22.26%, down 1442.0% from the prior year.
- Gross Margin eased to 47.12% in Q1 2026 per SXTP's latest filing, from 60.22% in the prior quarter.
- Across five years, Gross Margin topped out at 82.74% in Q2 2022 and bottomed at 325.81% in Q1 2023.
- Historically, Gross Margin has averaged 3.29% across 5 years, with a median of 38.08% in 2024.
- Annual changes were most pronounced in 2023 — Gross Margin sank 11387 bps — and 2024, when it jumped 36389 bps.
- 60 Degrees Pharmaceuticals' Gross Margin stood at 45.13% in 2022, then tumbled by 117 bps to 7.57% in 2023, then jumped by 776 bps to 51.13% in 2024, then gained by 18 bps to 60.22% in 2025, then fell by 22 bps to 47.12% in 2026.
- Business Quant data shows SXTP's Gross Margin at 47.12% in Q1 2026, 60.22% in Q4 2025, and 22.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 2.95 Mn | 1.92 Mn | 56,798.00 | 27.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.12% |
| Dec 31, 2025 | 60.22% |
| Sep 30, 2025 | -22.87% |
| Jun 30, 2025 | 50.41% |
| Mar 31, 2025 | 55.20% |
| Dec 31, 2024 | 51.13% |
| Sep 30, 2024 | 17.45% |
| Jun 30, 2024 | 28.33% |
| Mar 31, 2024 | 38.08% |
| Dec 31, 2023 | -7.57% |
| Sep 30, 2023 | -39.09% |
| Jun 30, 2023 | -31.13% |
| Mar 31, 2023 | -325.81% |
| Sep 30, 2022 | 45.13% |
| Jun 30, 2022 | 82.74% |